| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 28 oct 2026Próximo | Q3 2026 | — | 0,68 | 1,36 B |
1 sept 2026
Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
SAN DIEGO, September 01, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.
31 ago 2026
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
27 ago 2026
Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.
Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.
25 ago 2026
ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.
20 ago 2026
Dexcom (DXCM) passes strong growth & technical screens with high scores, solid fundamentals, and a bull flag breakout setup.
18 ago 2026
DexCom stock has gained 33.4% year to date, yet the valuation picture is mixed, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to meaningful upside while the broader checks lean less generous. For investors, the question is how to weigh a DCF signal that suggests the shares trade at a discount against a low overall value score. Year to date, DexCom is up 33.4%, which puts more pressure on the current price to be supported by future cash flows. Expectations...
17 ago 2026
DexCom stock reacts to recent performance and fundamentals DexCom (DXCM) has attracted investor attention after a recent share price move, with the stock closing at US$89.75. The company’s returns over the past month and past 3 months now stand out against its longer term record. See our latest analysis for DexCom. Short term momentum in DexCom has been strong, with the 30 day share price return of 17.09% and the 90 day share price return of 34.06% contrasting with a more modest 1 year total...
DexCom’s latest analyst work shows a modest lift in the modelled fair value, with the price target figure moving from US$91.64 to US$94.12. This adjustment sits alongside mixed analyst commentary that balances positive Q2 2026 execution, new clinical data and guidance updates, and ongoing questions about valuation and sector sentiment. As you read on, you will see how these moving parts shape the current story around DexCom and how to keep track of future shifts in the narrative. Stay updated...
14 ago 2026
Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.
13 ago 2026
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
12 ago 2026
DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.
DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.
DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.
DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.
4 ago 2026
DexCom earns a 7/10 fundamental rating, blending strong growth, reasonable valuation, and solid profitability as an affordable growth pick.
